C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022'; C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.
The report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022' outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Central Nervous System, Oncology, Respiratory, Gastrointestinal and Toxicology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Coronavirus Disease 2019 (COVID-19), Multiple Sclerosis, Chronic Obstructive Pulmonary Disease (COPD), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19) Pneumonia, Diabetic Neuropathic Pain, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Opioid Induced Side Effects, Opium (Opioid) Addiction, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Post-Acute Sequelae of COVID 2019 (PASC or Long COVID), Post-Operative Pain, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022'; C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.
The report 'C-C Chemokine Receptor Type 5 - Drugs In Development, 2022' outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Central Nervous System, Oncology, Respiratory, Gastrointestinal and Toxicology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Coronavirus Disease 2019 (COVID-19), Multiple Sclerosis, Chronic Obstructive Pulmonary Disease (COPD), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Bladder Cancer, Bone Metastasis, Colon Carcinoma, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19) Pneumonia, Diabetic Neuropathic Pain, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Opioid Induced Side Effects, Opium (Opioid) Addiction, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Post-Acute Sequelae of COVID 2019 (PASC or Long COVID), Post-Operative Pain, Testicular Cancer, Throat Cancer, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)
- The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
American Gene Technologies International Inc
Aphios Corp
Bristol-Myers Squibb Co
Creative Bio-Peptides Inc
Cytodyn Inc
Forest Hills Partners Hong Kong Ltd
GSK plc
Merck & Co Inc
Novartis AG
Orion Biotechnology Canada Ltd
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
(cenicriviroc + tropifexor) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AG-1105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APH-1701 - Drug Profile
Product Description
Mechanism Of Action
BMS-813160 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
DS-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DS-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DS-005 - Drug Profile
Product Description
Mechanism Of Action
History of Events
leronlimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
maraviroc - Drug Profile
Product Description
Mechanism Of Action
History of Events
maraviroc - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile
Product Description
Mechanism Of Action
History of Events
OB-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OB-002M - Drug Profile
Product Description
Mechanism Of Action
History of Events
RAP-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vicriviroc - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
Featured News & Press Releases
Jul 28, 2022: American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
Jul 19, 2022: Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression
Jul 14, 2022: Preclinical data demonstrate potential of Creative Bio-Peptides’ multi-chemokine receptor antagonist RAP-103 to provide opioid sparing post-surgical pain relief and treatment for chronic pain
Jul 11, 2022: CytoDyn highlights NIH Grant for HIV functional cure preclinical study of gene therapy based on leronlimab
Apr 12, 2022: CytoDyn announces publication of peer-reviewed paper, “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody leronlimab in two species”
Mar 31, 2022: FDA places full clinical hold on CytoDyn’s Covid-19 programme
Feb 24, 2022: American Gene Technologies advances closer to demonstrating a potential cure for HIV
Feb 02, 2022: American Gene Technologies’ HIV clinical trial shows blood markers of efficacy in two more patients
Jan 25, 2022: CytoDyn announces leadership transition plan to support regulatory approval and commercialization of Leronlimab
Jan 13, 2022: CytoDyn cancels webcast and live Q/A scheduled for today
Jan 10, 2022: Published paper indicates leronlimab shows activity against 4-class drug resistant HIV-1 from heavily treatment experienced (“HTE") subjects
Jan 05, 2022: Leronlimab 14-week, NASH clinical trial met primary endpoint (PDFF) and secondary endpoint (cT1) for per protocol population in 350 mg weekly dose
Dec 22, 2021: FDA provides positive response to begin CytoDyn’s Covid-19 antibody trial
Dec 21, 2021: American Gene Technologies’ HIV clinical trial demonstrates blood markers of efficacy
Dec 13, 2021: NASH phase 2 trial open-label portion demonstrates average 80 msec cT1 reduction in 50% of patients and reduction of nearly 50 msec in 80% of patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development
American Gene Technologies International Inc
Aphios Corp
Bristol-Myers Squibb Co
Creative Bio-Peptides Inc
Cytodyn Inc
Forest Hills Partners Hong Kong Ltd
GSK plc
Merck & Co Inc
Novartis AG
Orion Biotechnology Canada Ltd
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles
(cenicriviroc + tropifexor) - Drug Profile
Product Description
Mechanism Of Action
History of Events
AG-1105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
APH-1701 - Drug Profile
Product Description
Mechanism Of Action
BMS-813160 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
DS-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DS-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DS-005 - Drug Profile
Product Description
Mechanism Of Action
History of Events
leronlimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
maraviroc - Drug Profile
Product Description
Mechanism Of Action
History of Events
maraviroc - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile
Product Description
Mechanism Of Action
History of Events
OB-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OB-002M - Drug Profile
Product Description
Mechanism Of Action
History of Events
RAP-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vicriviroc - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones
Featured News & Press Releases
Jul 28, 2022: American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
Jul 19, 2022: Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression
Jul 14, 2022: Preclinical data demonstrate potential of Creative Bio-Peptides’ multi-chemokine receptor antagonist RAP-103 to provide opioid sparing post-surgical pain relief and treatment for chronic pain
Jul 11, 2022: CytoDyn highlights NIH Grant for HIV functional cure preclinical study of gene therapy based on leronlimab
Apr 12, 2022: CytoDyn announces publication of peer-reviewed paper, “Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody leronlimab in two species”
Mar 31, 2022: FDA places full clinical hold on CytoDyn’s Covid-19 programme
Feb 24, 2022: American Gene Technologies advances closer to demonstrating a potential cure for HIV
Feb 02, 2022: American Gene Technologies’ HIV clinical trial shows blood markers of efficacy in two more patients
Jan 25, 2022: CytoDyn announces leadership transition plan to support regulatory approval and commercialization of Leronlimab
Jan 13, 2022: CytoDyn cancels webcast and live Q/A scheduled for today
Jan 10, 2022: Published paper indicates leronlimab shows activity against 4-class drug resistant HIV-1 from heavily treatment experienced (“HTE") subjects
Jan 05, 2022: Leronlimab 14-week, NASH clinical trial met primary endpoint (PDFF) and secondary endpoint (cT1) for per protocol population in 350 mg weekly dose
Dec 22, 2021: FDA provides positive response to begin CytoDyn’s Covid-19 antibody trial
Dec 21, 2021: American Gene Technologies’ HIV clinical trial demonstrates blood markers of efficacy
Dec 13, 2021: NASH phase 2 trial open-label portion demonstrates average 80 msec cT1 reduction in 50% of patients and reduction of nearly 50 msec in 80% of patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by American Gene Technologies International Inc, 2022
Pipeline by Aphios Corp, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Creative Bio-Peptides Inc, 2022
Pipeline by Cytodyn Inc, 2022
Pipeline by Forest Hills Partners Hong Kong Ltd, 2022
Pipeline by GSK plc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Orion Biotechnology Canada Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by American Gene Technologies International Inc, 2022
Pipeline by Aphios Corp, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Creative Bio-Peptides Inc, 2022
Pipeline by Cytodyn Inc, 2022
Pipeline by Forest Hills Partners Hong Kong Ltd, 2022
Pipeline by GSK plc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Orion Biotechnology Canada Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
